FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154024747> ?p ?o ?g. }

• W3154024747 endingPage "1836" @default.
• W3154024747 startingPage "1825" @default.
• W3154024747 abstract "Abstract Over the past decade, several drugs have been approved for the treatment of relapsed or refractory multiple myeloma (RRMM). This retrospective study, using the French National Healthcare database (SNDS), describes the treatment patterns and outcomes of patients with RRMM treated in real-world clinical practice in France. Patients were adults, with a diagnosis of multiple myeloma, who initiated second-line (2L) treatment approved for use in France between 2014 and 2018; this included bortezomib, carfilzomib, daratumumab, ixazomib, lenalidomide, or pomalidomide. Data were analyzed overall, by first-line (1L) autologous stem cell transplant (ASCT) status and by lenalidomide treatment status at 2L. In total, 12987 patients with RRMM were included in the study (mean age 69.5 years); 27% received an ASCT at 1L, and 30% received a lenalidomide-sparing regimen at 2L. Overall, and among the ASCT and non-ASCT subgroups, most patients received a bortezomib-based regimen at 1L, whereas lenalidomide-based regimens were most common at 2L. Among patients who received a lenalidomide-sparing regimen at 2L, this was most often a proteasome inhibitor-based regimen. Mortality rate was 26.1/100 person-years, and median (95% confidence interval) survival from 2L initiation was 32.4 (31.2–33.6) months. Survival differed by various factors, shorter survival was reported in the non-ASCT group, those receiving a lenalidomide-sparing regimen at 2L, older patients (≥ 70 years), and those with multiple comorbidities. This analysis provides insight into the real-world use of approved novel MM treatments and highlights an ongoing unmet need to improve outcomes, particularly for selected patient groups." @default.
• W3154024747 created "2021-04-26" @default.
• W3154024747 creator A5000316108 @default.
• W3154024747 creator A5003428531 @default.
• W3154024747 creator A5008339206 @default.
• W3154024747 creator A5025681291 @default.
• W3154024747 creator A5027106419 @default.
• W3154024747 creator A5045592355 @default.
• W3154024747 creator A5057347177 @default.
• W3154024747 creator A5063754167 @default.
• W3154024747 creator A5065853518 @default.
• W3154024747 date "2021-04-21" @default.
• W3154024747 modified "2023-10-18" @default.
• W3154024747 title "Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)" @default.
• W3154024747 cites W1535093614 @default.
• W3154024747 cites W1985864219 @default.
• W3154024747 cites W2096367061 @default.
• W3154024747 cites W2162771614 @default.
• W3154024747 cites W2199914463 @default.
• W3154024747 cites W2201190784 @default.
• W3154024747 cites W2343386476 @default.
• W3154024747 cites W2443618845 @default.
• W3154024747 cites W2460376887 @default.
• W3154024747 cites W2509056157 @default.
• W3154024747 cites W2512106959 @default.
• W3154024747 cites W2528329272 @default.
• W3154024747 cites W2588087999 @default.
• W3154024747 cites W2588220165 @default.
• W3154024747 cites W2736522376 @default.
• W3154024747 cites W2749746182 @default.
• W3154024747 cites W2765308329 @default.
• W3154024747 cites W2790465490 @default.
• W3154024747 cites W2791002232 @default.
• W3154024747 cites W2885738414 @default.
• W3154024747 cites W2887279750 @default.
• W3154024747 cites W2890436368 @default.
• W3154024747 cites W2898136397 @default.
• W3154024747 cites W2899675310 @default.
• W3154024747 cites W2913976792 @default.
• W3154024747 cites W2920787201 @default.
• W3154024747 cites W2925264218 @default.
• W3154024747 cites W2945852816 @default.
• W3154024747 cites W2952354236 @default.
• W3154024747 cites W2986528939 @default.
• W3154024747 cites W2988984460 @default.
• W3154024747 cites W2989323988 @default.
• W3154024747 cites W3015070914 @default.
• W3154024747 cites W3036660876 @default.
• W3154024747 cites W3093835197 @default.
• W3154024747 cites W3119560825 @default.
• W3154024747 cites W3127065235 @default.
• W3154024747 doi "https://doi.org/10.1007/s00277-021-04522-y" @default.
• W3154024747 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8195931" @default.
• W3154024747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33884454" @default.
• W3154024747 hasPublicationYear "2021" @default.
• W3154024747 type Work @default.
• W3154024747 sameAs 3154024747 @default.
• W3154024747 citedByCount "6" @default.
• W3154024747 countsByYear W31540247472022 @default.
• W3154024747 countsByYear W31540247472023 @default.
• W3154024747 crossrefType "journal-article" @default.
• W3154024747 hasAuthorship W3154024747A5000316108 @default.
• W3154024747 hasAuthorship W3154024747A5003428531 @default.
• W3154024747 hasAuthorship W3154024747A5008339206 @default.
• W3154024747 hasAuthorship W3154024747A5025681291 @default.
• W3154024747 hasAuthorship W3154024747A5027106419 @default.
• W3154024747 hasAuthorship W3154024747A5045592355 @default.
• W3154024747 hasAuthorship W3154024747A5057347177 @default.
• W3154024747 hasAuthorship W3154024747A5063754167 @default.
• W3154024747 hasAuthorship W3154024747A5065853518 @default.
• W3154024747 hasBestOaLocation W31540247471 @default.
• W3154024747 hasConcept C126322002 @default.
• W3154024747 hasConcept C141071460 @default.
• W3154024747 hasConcept C143998085 @default.
• W3154024747 hasConcept C2776063141 @default.
• W3154024747 hasConcept C2776364478 @default.
• W3154024747 hasConcept C2777478702 @default.
• W3154024747 hasConcept C2778524551 @default.
• W3154024747 hasConcept C2779050716 @default.
• W3154024747 hasConcept C2779609412 @default.
• W3154024747 hasConcept C2780108899 @default.
• W3154024747 hasConcept C2781098529 @default.
• W3154024747 hasConcept C2781119759 @default.
• W3154024747 hasConcept C2781413609 @default.
• W3154024747 hasConcept C71924100 @default.
• W3154024747 hasConceptScore W3154024747C126322002 @default.
• W3154024747 hasConceptScore W3154024747C141071460 @default.
• W3154024747 hasConceptScore W3154024747C143998085 @default.
• W3154024747 hasConceptScore W3154024747C2776063141 @default.
• W3154024747 hasConceptScore W3154024747C2776364478 @default.
• W3154024747 hasConceptScore W3154024747C2777478702 @default.
• W3154024747 hasConceptScore W3154024747C2778524551 @default.
• W3154024747 hasConceptScore W3154024747C2779050716 @default.
• W3154024747 hasConceptScore W3154024747C2779609412 @default.
• W3154024747 hasConceptScore W3154024747C2780108899 @default.
• W3154024747 hasConceptScore W3154024747C2781098529 @default.
• W3154024747 hasConceptScore W3154024747C2781119759 @default.
• W3154024747 hasConceptScore W3154024747C2781413609 @default.

• next